MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM). Numerous MDM2 inhibitors have been developed and are currently undergoing rigorous testing for their potential in GBM therapy. Encouraging resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellot Ortiz, Karolina I., Rechberger, Julian S., Nonnenbroich, Leo F., Daniels, David J., Sarkaria, Jann N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377337/
https://www.ncbi.nlm.nih.gov/pubmed/37509518
http://dx.doi.org/10.3390/biomedicines11071879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377337/
https://www.ncbi.nlm.nih.gov/pubmed/37509518
http://dx.doi.org/10.3390/biomedicines11071879

Ejemplares similares